Globela Pharma - Globela Pharma Pvt Ltd.

Generic Medicines: Importance, Challenges, and the Future of Affordable Healthcare

Generic medicines are essential in healthcare, offering affordable alternatives to brand-name drugs. They provide the same benefits as branded medications but at a much lower cost, making treatments more accessible, especially in lower and middle-income countries where healthcare can be expensive.

Beyond affordability, generic medicines encourage competition in the pharmaceutical industry, driving down drug prices and promoting innovation. However, developing these medicines isn’t without challenges. Companies face complex regulations, patent issues, and the need to maintain high quality.

In this article, we’ll discuss why generic medicines are important, the challenges in creating them, and solutions to these problems. We can ensure that more people can access the necessary medicines by addressing these challenges.

The Importance of Generic Medicines

Generic medicines serve as a cornerstone in healthcare, offering cost-effective alternatives to brand-name drugs without compromising quality. They are crucial for ensuring that more people can access necessary treatments, especially in the face of rising healthcare costs.

Affordable Healthcare Access

One of the biggest benefits of generic medicines is their lower cost. Since generic manufacturers don’t have to spend on research and development like brand-name companies, they can offer the same medicines at much lower prices.

This affordability is essential in lower- and middle-income countries with tight healthcare budgets. By making medicines more accessible, generics help improve public health and ease the financial strain on healthcare systems.

Promoting Market Competition

Generic medicines also create healthy competition in the pharmaceutical market. When a brand-name drug’s patent expires, generics enter the market, pushing prices down and encouraging brand-name companies to lower their prices.

This competition benefits consumers by making medicines more affordable and drives innovation in the industry. To stay competitive, companies are motivated to develop new and better treatments.

Ensuring Drug Availability

Generics play a crucial role in ensuring that essential medicines are always available. Sometimes, brand-name drugs might face shortages due to production issues or supply chain problems. Generics can fill this gap, ensuring that patients continue to have access to the medicines they need.

Additionally, having more generic options broadens treatment choices, especially for patients with chronic conditions. This wider access helps improve patient outcomes and control healthcare costs.

Reducing Healthcare System Burdens

Generic medicines play a significant role in easing the financial burden on healthcare systems. By offering more affordable treatment options, generics help reduce overall healthcare spending, allowing governments and insurance providers to allocate resources more effectively.

This cost-saving aspect is particularly important in countries with limited healthcare budgets, where the widespread use of generics can lead to substantial savings and enable the funding of other critical health services.

Supporting Global Health Initiatives

Generic medicines are essential in supporting global health initiatives, particularly in the fight against widespread diseases like HIV, malaria, and tuberculosis. Many international health organizations rely on generics to provide life-saving treatments to millions of people in developing countries.

By making these medicines more accessible and affordable, generics improve health outcomes globally and help drive progress towards achieving universal health coverage.

Challenges in Developing Generic Medicines

Developing generic medicines is vital for making healthcare more affordable. Still, it comes with its challenges, which can delay generics from reaching the market, limit competition, and reduce patient access to essential medicines.

Regulatory Hurdles

Getting generic medicines approved involves navigating complex and varied regulatory processes across different countries. Regulatory bodies like the FDA and EMA require generics to demonstrate bioequivalence to the original branded drugs, ensuring they are as safe and effective.

However, this can be a slow and complicated process. To overcome this:

Harmonize Global Standards: Work towards consistent regulations worldwide to simplify approval.
Fast-Track Approvals: Create expedited review pathways for essential generics.
Improve Transparency: Enhance communication between regulators and manufacturers.
Offer Regulatory Support: Provide guidance, especially in lower-income countries.
Reduce Paperwork: Simplify administrative processes to cut down delays.

Patent and Legal Barriers

Patent protections for brand-name drugs often prevent generics from entering the market. Brand-name manufacturers may extend patents or engage in legal battles to delay the release of generic alternatives, limiting competition and keeping drug prices high.

To mitigate this:

Prevent Patent Extensions: Implement policies to stop minor changes that extend patents.
Support Generic-First Policies: Prioritize generics once original patents expire.
Strengthen Legal Frameworks: Resolve patent disputes quickly and fairly.
Facilitate Settlements: Encourage faster settlements to avoid prolonged legal battles.
Incentivize Challenges: Reward companies that challenge weak patents.

Manufacturing and Quality Control

Ensuring that generic medicines are manufactured to the same quality standards as branded drugs is crucial. Generic manufacturers must prove that their products are bioequivalent, meaning they perform the same way as the original.

Maintaining consistent quality across batches is a significant challenge. So, make sure to:

Adopt Continuous Manufacturing: Use modern techniques to ensure consistent quality.
Leverage Predictive Analytics: Use AI to monitor and improve production processes.
Strengthen Supply Chains: Ensure reliable access to high-quality raw materials.
Implement Quality Assurance: Monitor all production stages rigorously.
Invest in Training: Keep staff updated on the latest manufacturing practices.

Bottom Line

Generic medicines are essential for making healthcare more affordable and accessible. They offer cost-effective alternatives to brand-name drugs, which help lower overall healthcare costs, promote competition, and ensure the availability of crucial treatments.

However, developing generic medicines comes with challenges like complex regulations, legal issues, and manufacturing difficulties. To address these, companies like Globela Group are leading the way by streamlining regulatory processes, fostering public-private partnerships, and investing in advanced technologies.

By tackling these challenges, we can improve the availability and quality of generic medicines, ultimately benefiting global healthcare and positively impacting countless lives.

Closing the Healthcare Gap: Affordable Medicines for Lower and Middle-Income Countries

In lower and middle-income countries (LMICs), healthcare access is a significant challenge. The WHO reports that nearly two billion people globally struggle to access essential medicines, with about 80% of the world’s population living in countries with minimal or no access to pain relief medications. This gap leads to preventable illnesses and deaths, affecting communities on a large scale.

Safe and affordable medicines are crucial in addressing this disparity. Globela Pharma focuses on recognizing this with their vision, “Every Life is Precious.” Their mission is to ensure that everyone can access high-quality, affordable medicines no matter where they live. They’re actively bridging the healthcare gap by delivering these medicines across more than 50 countries, including key regions in Africa and Latin America.

In this article, let’s look at how affordable yet quality medicines are essential to improving healthcare in lower and middle-income countries.

The Healthcare Challenge in LMICs

Addressing healthcare in lower and middle-income countries (LMICs) is vital for global health equity. Here are the key challenges:

Access to Essential Medicines: Many people can’t get necessary medications due to high costs and poor supply chains.
High Medications Costs: Prices are often too high for many individuals, leaving crucial treatments out of reach.
Burden of Disease: Common conditions like malaria, tuberculosis, and diabetes can lead to severe health issues if not treated.
Impact on Economic Growth: Poor health affects productivity and economic development as sick individuals struggle to work or study.
Inadequate Healthcare Infrastructure: Limited facilities and resources in many LMICs make it hard to provide effective care.

The Importance of Safe and Affordable Medicines

Safe and affordable medicines are crucial for closing the healthcare gap, especially in lower and middle-income countries (LMICs). Here’s why they’re so important:

Ensuring Safety and Quality

First off, safety is a big deal. You wouldn’t want to take medicine that could harm you or doesn’t work. In many LMICs, the risk of encountering counterfeit or poor-quality medications is high, which can lead to serious health issues. It can be harmful to your kidneys, heart, stomach, and other organs as well.

Therefore, maintaining quality assurance is also important to ship high-quality medicine worldwide. Also, ensuring safety and quality under laws and regulations allows companies to inspect the entire manufacturing process. So, pharmaceutical companies must develop ways to innovate more efficient yet safest medicine.

Ensuring that medicines meet high safety and quality standards is key to protecting health and effective treatment.

Making Medicines Affordable

Affordability is equally crucial. Imagine needing medication but finding it’s priced out of your reach. High costs can mean people skip essential treatments, leading to worse health outcomes.

According to research data, one-third of the world’s population lacks regular access to essential medicines. And, one of the main reasons for it in low and middle-income countries is high-pricing medicine.

By making medicines more affordable, we at Globela Pharma, ensure that more people can access the treatments they need, which can significantly improve their health and quality of life.

Bridging Health Gaps

Affordable medicines help bridge the health gap between different income levels. When medications are within reach for everyone, it means fairer access to treatment and a chance for a healthier life, no matter your financial situation.

Around the world, especially in low and middle-income countries, the common causes of death are malaria, infectious disease, and HIV/AIDS, which can be effectively prevented or treated by appropriate medicines. Thus, providing affordable medications will help in bridging health gaps.

Supporting Ongoing Health

Access to affordable medicines isn’t just about immediate relief; it’s about long-term health. Consistent access to necessary medications helps manage chronic conditions and prevents diseases from worsening. This support strengthens not just individual health but also the overall health system.

A Vision for Change: Every Life is Precious

In a world where healthcare remains out of reach for too many, the belief at Globela Group that ‘Every Life is Precious’ drives a mission to make a real difference. This isn’t just a catchy slogan; it’s a commitment to ensuring no one is left behind when accessing life-saving medicines. Imagine a world where every person, regardless of where they live or their financial situation, has access to the high-quality treatments they need. That’s the vision.

Commitment to Accessibility

At the heart of this vision at Globela, is a simple but powerful idea: everyone deserves access to safe, effective, and affordable medicines. It’s about breaking down barriers and reaching every corner of society, from bustling urban centers to the most remote villages. This commitment isn’t just about making medicines available; it’s about making them truly accessible to those who need them most.

When medicines are affordable, they aren’t just products on a shelf—they become lifelines, offering hope and healing to millions. And that’s what this vision aims to achieve: turning accessibility into reality, one community at a time.

Reaching Global Communities

The reach of Globela Group’s mission spans across over 50 countries, including key regions in Africa and Latin America. These are areas where healthcare gaps are often the widest, and the need for affordable medicines is the greatest. By establishing a strong presence in these regions, the goal is to bring high-quality treatments to those who might otherwise go without.

But it’s not just about numbers or locations—it’s about impact.

Each country and community touched by this mission represents a step toward a world where healthcare isn’t a luxury but a fundamental right. The effort to make this vision a reality is ongoing, where every new partnership and every new outreach effort brings us closer to a future where everyone, everywhere, has the chance to live a healthier life.

Closing the healthcare gap in lower and middle-income countries is crucial. Safe, affordable medicines are a right everyone should have.

Globela Group believes that “Every Life is Precious” guides its mission to make this a reality, bringing hope and better health to 50+ countries. The challenge of bridging the gap is enormous. Still, Globela Group’s focus on quality, safety, and affordability is helping create a future where everyone, no matter where they live, can access the healthcare they deserve.

3D render of a medical image with virus cells

Attacking Cancer Cells That Develop Resistance

Cancer remains one of the most intimating challenges in modern medicine, affecting millions of lives worldwide. While cancer treatment progress has been significant, resistance to therapies remains a serious challenge. Cancer cells often adapt and develop resistance to treatments that were once effective, leading to treatment failure and disease progression.

This article explores resistant cancer cells and current strategies to overcome them. Understanding resistance mechanisms and using advanced treatments can ensure successful treatment outcomes despite resistance challenges.

Understanding Cancer Cell Resistance

Cancer treatment faces a significant challenge: cancer cells become resistant to therapies that once worked. These resistance mechanisms vary from genetic mutations and epigenetic changes within cancer cells to the influence of the tumor microenvironment.

The consequences of untreated or recurrent cancer due to resistance are dire, often leading to poor outcomes and decreased quality of life for patients. Despite advancements in our understanding of these mechanisms, overcoming resistance remains a daunting task. The situation demands a collective effort to address this issue head-on.

Moreover, the economic burden of ineffective treatments adds another layer of urgency to the search for solutions. To combat this, it’s crucial to understand these mechanisms and find ways to target resistant cancer cells effectively.

Mechanisms of Resistance

Genetic Mutations: Cancer cells can develop genetic mutations over time, making them less responsive to treatment. These mutations affect important cell functions, allowing cancer cells to survive and grow despite treatment.
Epigenetic Changes: Changes in gene activity, called epigenetic alterations, also contribute to resistance. These changes can silence genes that control cancer growth or activate genes that promote it, making treatment less effective.
Tumor Microenvironment: The environment around tumors plays a role too. Factors like low oxygen, inflammation, and nearby cells can protect cancer cells from treatment, making them harder to kill.

Importance of Finding Strategies to Attack Resistant Cancer Cells

Preserving Treatment Efficacy: Resistant cancer cells make treatments that used to work ineffective, lowering survival chances. Finding strategies to overcome resistance helps keep treatments working longer, improving patient outcomes.
Expanding Treatment Options: Overcoming resistance means more treatment options for patients. Clinicians can tailor treatment regimens to individual patients by targeting resistant cancer cells and optimizing therapeutic outcomes.
Enhancing Survival Rates: Effective strategies to attack resistant cancer cells prolong patient survival. By preventing or delaying disease progression, these strategies offer hope for better long-term outcomes.
Addressing Heterogeneity: Resistant cells within tumors vary, showing different resistance levels to specific treatments. Targeting resistant cells helps in reducing the likelihood of treatment failure and disease recurrence.

Current Strategies to Overcome Resistance

Researchers are exploring various innovative strategies to combat cancer cells that develop resistance to treatments. By understanding the underlying resistance mechanisms, these approaches aim to eliminate resilient cancer cells more effectively.

Here are some of the most promising methods being used today.

Targeting Cell-Cycle Kinase Inhibitors

Cell-cycle kinase inhibitors offer a promising solution against cancer resistance. These drugs slow or halt tumor growth by targeting cyclin-dependent kinases (CDKs). CDK inhibitors are effective, especially in hormone receptor-positive breast cancer, and reactivate natural tumor suppressors.

Yet, cancer cells adapt, driving research into next-gen inhibitors targeting additional cell division enzymes. Consequently, early trials show potential for more effective, longer-lasting treatments, pushing researchers to innovate and outpace cancer’s adaptability for better patient outcomes.

Targeted Therapies

Targeted therapies focus on specific molecular targets linked to cancer. These treatments disrupt cancer cell growth and survival. For example, tyrosine kinase inhibitors (TKIs) block signals that make cancer cells grow. Even though resistance can occur through new mutations, targeted therapies like Imatinib for chronic myeloid leukemia (CML) and Trastuzumab for HER2-positive breast cancer have shown great success. They work best when combined with other treatments to help prevent resistance.

Combination Therapies

Combination therapies use multiple treatments to attack cancer cells from different angles, reducing the chance of resistance. This approach can include chemotherapy, targeted therapy, and immunotherapy. For example, combining BRAF and MEK inhibitors effectively treat melanoma by targeting different parts of the same pathway. This makes it harder for cancer cells to survive. Studies show that combination therapies improve response rates and extend progression-free survival, though managing side effects and interactions is important.

Immunotherapy

Immunotherapy uses the body’s immune system to fight cancer, making it a strong tool against resistant tumors. Checkpoint inhibitors like Pembrolizumab and Nivolumab block proteins that stop immune cells from attacking cancer. CAR-T cell therapy modifies a patient’s T-cells to target cancer more effectively and has been successful in certain blood cancers. Immunotherapy’s ability to adapt to cancer cells helps overcome resistance. Research is ongoing to enhance its effectiveness and manage side effects.

Nanotechnology

Nanotechnology uses nanoparticles to deliver drugs directly to cancer cells, increasing drug concentration at the tumor while reducing overall side effects. This approach can bypass resistance mechanisms like drug efflux pumps. Recent advances show that nanomedicine can improve the effectiveness of chemotherapy and targeted therapies.

Gene Editing and CRISPR

Gene editing tools like CRISPR can modify or correct genes responsible for cancer resistance. By targeting specific genes in resistance pathways, CRISPR can restore treatment sensitivity. Though still experimental, this technique shows promise for precision medicine despite ethical and technical challenges.

Emerging Experimental Treatments

New experimental treatments are being explored to fight resistant cancer cells. These include novel small molecules, antisense oligonucleotides, and adaptive therapy strategies. These innovative approaches are in various stages of research and trials, showing potential for future use in overcoming resistance.

Bottom Line

In our quest against cancer, resistant cancer cells stand as formidable opponents. Yet, with advancing knowledge and technology, we have potent weapons at our disposal. We’ve explored various strategies to combat resistance, from targeted therapies to immunotherapy and cutting-edge techniques like nanotechnology and gene editing.

Similarly, we at Globela, are open for collaboration across disciplines and borders, driven by the goal of defeating cancer. Globela’s Oncology department is committed to offering the highest quality products at affordable prices so that as many people as possible can benefit.

Whether you are a patient, a caregiver, or a healthcare professional, we are here to help you in your journey towards a cancer-free future.

Transforming Metastatic Breast Cancer Treatment: The Critical Role of Independent Research

Metastatic breast cancer (MBC) is a serious and complex form of cancer that continues to challenge researchers and clinicians. While there have been advancements in treating early-stage breast cancer, MBC remains difficult to manage and treat effectively. Independent scientific research is crucial in finding new ways to understand and combat this disease.

This article explores the latest discoveries in MBC research, focusing on how independent studies make a real difference in patient care.

Introduction

Metastatic breast cancer (MBC), or stage IV breast cancer, occurs when cancer spreads from the breast to other parts of the body like bones, liver, lungs, or brain. Unlike early-stage breast cancer, MBC isn’t curable and needs lifelong treatment. However, advancements in research are crucial for improving patient outcomes and quality of life.

Importance of Advancements in MBC Research

Improving Survival Rates: New treatments can help patients live longer.
Enhancing Quality of Life: Research leads to therapies that manage symptoms and reduce side effects.
Personalized Medicine: Discoveries enable tailored treatments based on individual genetics, improving effectiveness and reducing unnecessary treatments.
Understanding Metastasis: Insights into how and why cancer spreads can lead to new preventative measures and treatments.

The Current State of Metastatic Breast Cancer

MBC affects many individuals worldwide. In the United States, it is estimated more than 168,000 women will be living with metastatic breast cancer in 2020. Despite advances in detection and treatment, MBC remains a leading cause of cancer-related deaths among women, with a median survival of about three years after diagnosis.

Challenges in Treating MBC Compared to Early-Stage Breast Cancer

Complex Treatment: Early-stage breast cancer can often be treated with surgery and localized therapies. MBC requires systemic treatments like targeted therapy and immunotherapy to address cancer cells throughout the body.
Treatment Resistance: Metastatic cancer cells can develop resistance to treatments, reducing their effectiveness and necessitating new therapies and combinations.
Tumor Diversity: MBC tumors often contain different types of cancer cells, making it difficult to find a one-size-fits-all treatment. Different cells may respond differently to the same therapy.
Quality of Life: Managing MBC involves not only controlling cancer spread but also addressing symptoms and side effects, such as pain, fatigue, and emotional distress, which impact the patient’s quality of life.

The Role of Independent Scientific Research

Independent scientific research is conducted by researchers or organizations not directly affiliated with major institutions or government bodies. It is often funded by private foundations, non-profits, or individual donors, allowing for greater flexibility and innovation.

It is important for the following reasons:

Innovation and Flexibility: Independent researchers can explore new ideas and approaches that larger institutions might overlook.
Filling Knowledge Gaps: They can study areas that are often underfunded, contributing to a more complete understanding of MBC.
Collaboration and Cross-Disciplinary Work: Independent groups often work with other researchers, patients, and advocacy groups, fostering a comprehensive approach to finding solutions.
Rapid Response to Emerging Data: These researchers can quickly adapt to new findings, ensuring the latest discoveries are promptly investigated and translated into treatments.

Recent Breakthroughs in MBC Research

In the relentless pursuit of combating metastatic breast cancer (MBC), recent years have seen remarkable breakthroughs that are reshaping the landscape of treatment options and patient outcomes. These breakthroughs result from tireless efforts from independent researchers dedicated to unraveling the complexities of MBC.

Here’s a closer look at some of the most significant advancements:

On/Off Switch for MBC

In a recent study, researchers led by Lingyin Li, a Stanford biochemistry professor, found that the protein ENPP1 plays a key role in breast cancer’s resistance to immunotherapy and its spread. ENPP1 is found in both cancerous and healthy cells and is linked to immunotherapy resistance and metastasis in breast cancer patients.

Collaborating with UCSF professors, the team confirmed ENPP1’s predictive value in patient outcomes. Mouse studies showed that blocking ENPP1 reduced tumor growth and metastasis by suppressing the immune response. Dr Li suggested that ENPP1 acts like a “dam,” blocking immune signals and allowing cancer cells to hide.

These findings could help guide treatment decisions and improve therapies for breast cancer and other cancers that evade the immune system.

Two-pronged Immunotherapy for Metastatic Breast Cancer

Researchers at Washington University School of Medicine have found a way to make metastatic breast tumors in bone susceptible to the body’s immune system. By boosting certain immune cells, they cleared breast tumors in mice and prevented them from returning.

Blocking a molecule called p38 MAPK made the tumor area more vulnerable while combining it with an immune therapy called OX40 agonist supercharged T cells, effectively eliminating metastatic tumors.

This approach shows promise for treating metastatic breast cancer and protecting against bone loss. Clinical trials are ongoing for the therapies involved.

Targeting SMYD2 Protein to Prevent MBC

In a study published in Cell Discovery, researchers led by a biologist at CNRS have uncovered a potential breakthrough in understanding metastatic breast cancer. They found that a protein abundant in aggressive breast cancers, SMYD2, might play a pivotal role in promoting metastasis. This protein appears to activate BCAR3, another protein known for aiding cancer cell adhesion and migration.

Through experiments on mice with early-stage breast cancer, inhibiting SMYD2 prevented metastasis, suggesting a promising avenue for early treatment strategies that could potentially improve patient outcomes.

Translating Research into Patient Care

Recent progress in metastatic breast cancer (MBC) research is bringing hope to patients. Turning research into practical treatments follows a step-by-step process:

Lab Testing: New treatments are first tested in labs to make sure they’re safe and effective.
Clinical Trials: Promising treatments move to human trials, starting small to check safety and dosage, then expanding to see how well they work.
Regulatory Approval: Once proven safe and effective, treatments get approval from organizations like the FDA.
Guidelines and Monitoring: Approved treatments become part of official guidelines for doctors. They’re also watched closely to make sure they keep working well and are safe in the long run.

Bottom Line

Independent research is vital for advancing our understanding and treatment of metastatic breast cancer (MBC). Despite challenges, researchers have made significant breakthroughs, improving patient care. To sustain progress, we must support independent research efforts through funding and advocacy.

Looking ahead, personalized medicine offers hope for better outcomes. Let’s continue prioritizing and investing in independent research to provide hope and better solutions for MBC patients.

Revision. Two pharmacists making medicines revision in a drugstore

The Journey of a Drug: From R&D to Your Pharmacy Shelf

Every drug that reaches your pharmacy shelf undergoes a remarkable journey, traversing through various stages of research, development, manufacturing, and regulation. This journey is a testament to scientific innovation and a demonstration of stringent quality standards and regulatory compliance.

In this article, we delve into the comprehensive process of how a drug evolves from its conception in research and development (R&D) laboratories to its availability on the shelves of pharmacies worldwide. Along with a keen focus on the value chain expertise and the significance of WHO/EU GMP certifications.

Research & Development (R&D)

The research and development phase is at the heart of every drug’s journey. Here, pharmaceutical companies invest significant resources into discovering new molecules or repurposing existing ones to address unmet medical needs.

This phase involves many scientific disciplines, including medicinal chemistry, pharmacology, and toxicology. Researchers meticulously screen thousands of compounds, seeking those with the desired therapeutic effects and minimal side effects. Consequently, once a promising compound is identified, it undergoes preclinical testing, where its safety and efficacy are evaluated in laboratory settings and animal models. This stage is crucial for determining whether the compound warrants further development.

Clinical Trials

Upon successful completion of preclinical studies, the drug candidate progresses to clinical trials – the cornerstone of drug development. These trials are divided into phases and involve rigorous testing in human subjects to assess safety, efficacy, and optimal dosage. These phases are:

Phase 1: Primarily focuses on small-scale testing for safety and dosage in healthy volunteers.
Phase 2: Testing in a larger group to determine efficacy and side effects.
Phase 3: Large-scale testing in diverse populations to confirm efficacy and monitor adverse reactions.
Phase 4: Post-marketing surveillance for long-term safety and efficacy.

Regulatory Approval

Adherence to Good Manufacturing Practices (GMP) is central to the pharmaceutical value chain. GMPs are a set of quality assurance guidelines that ensure the consistent production of safe and effective pharmaceutical products. Recognizing the global nature of pharmaceutical manufacturing, organizations such as the World Health Organization (WHO) and the European Union (EU) have established GMP standards to harmonize quality standards worldwide.

Additionally, when a drug developer has gathered evidence demonstrating a drug’s safety and efficacy, they file a New Drug Application (NDA) with the FDA. This comprehensive document includes all relevant data from preclinical and clinical studies, proposed labeling, safety updates, and more.

Upon receiving the NDA, the FDA review team meticulously examines its contents. If deemed complete, the team has 6 to 10 months to decide on approval. Each team member conducts a thorough review, supplemented by on-site inspections, to ensure data integrity.

However, if the FDA determines the drug is safe and effective, labeling is refined to reflect its approved uses. Sometimes, additional studies or clarifications are requested before final approval.

Manufacturing

After regulatory approval, pharmaceuticals enter the manufacturing phase. This phase is marked by meticulous attention, stringent quality control, and advanced technology to ensure safe and effective drug production.

Raw Material Sourcing and Quality Assurance

Manufacturing starts with getting raw materials. Manufacturers carefully choose suppliers by checking their facilities to ensure the raw materials are pure and potent, avoiding contamination that could harm the final product. They also check if suppliers follow Good Manufacturing Practices (GMP) to maintain quality standards.

Formulation and Process Development

Pharmaceutical manufacturers optimize drug composition during formulation and process development for efficiency and patient compliance. Scientists assess solubility, stability, and administration routes. And, engineers design manufacturing processes for consistency and quality.

Manufacturing Operations and Quality Control

Pharmaceutical manufacturers move to large-scale production in advanced facilities, ensuring precise control. Each step is monitored for cleanliness and integrity, with quality control labs conducting comprehensive testing. This testing includes HPLC and mass spectrometry, to verify product quality and regulatory compliance.

Packaging and Distribution

After manufacturing, pharmaceutical products are packaged and labeled to safeguard against the environment and tampering while providing essential information. Manufacturers use various packaging formats tailored to dosage forms. These products are then distributed to wholesalers, distributors, and pharmacies, reaching patients.

Post-market Surveillance

Drug safety is a continuous process. Although clinical trials offer critical insights into a drug’s efficacy and safety, complete safety understanding isn’t immediate upon approval. A complete safety profile is only formed over time in the market. The FDA monitors drugs post-approval, updating information and issuing cautions or other measures if needed.

It includes changes via supplemental applications, new uses via INDs, and routine inspections of manufacturing facilities. The FDA also regulates drug advertising to ensure accuracy and prohibits unapproved uses. Moreover, programs like MedWatch and MedSun facilitate reporting problems and enhance post-market safety monitoring.

Collaboration Across the Value Chain: A Network of Expertise

The journey of a drug from R&D to the pharmacy shelf requires expertise at every stage of the value chain. Pharmaceutical companies collaborate with a diverse network of stakeholders, including scientists, clinicians, regulatory experts, and manufacturing professionals, to navigate the complexities of drug development and commercialization.

Research and development teams leverage their scientific power to identify promising drug candidates and optimize their properties for clinical use. Clinical researchers conduct trials with precision and adherence to ethical standards, generating robust data for regulatory submission. Regulatory affairs specialists liaise with regulatory agencies to ensure compliance with evolving guidelines and expedite the approval process.

In manufacturing facilities, engineers and technicians employ cutting-edge technologies to streamline production processes and maintain the highest standards of quality.

From Research to Market: A Journey of Expertise

The journey of a drug from conception to pharmacy shelves is a testament to scientific collaboration and regulatory diligence. From meticulous research and clinical trials to stringent manufacturing and post-market surveillance, each stage relies on a network of expertise.

Interdisciplinary collaboration and strict adherence to WHO/EU GMP standards guarantee safe, effective medications reach global patients. From research laboratories to manufacturing plants, each contributor plays a vital role in advancing the drug along its journey, culminating in its availability to patients in need.

Green Chemistry: A Catalyst for Transformation in Pharma Manufacturing

Green chemistry, also known as sustainable chemistry, has emerged as a hope for industries striving to minimize their environmental footprint while maximizing efficiency and innovation. Despite pharmaceutical companies’ significant economic contribution, their manufacturing processes contribute to carbon emissions. Pharmaceutical factories typically use dangerous chemicals and produce a lot of waste, but green chemistry can bring significant changes for a better environment. This article delves into how adopting green chemistry practices is necessary to revolutionize the future of pharmaceutical manufacturing.

Understanding Green Chemistry

Before exploring the implications of green chemistry for the pharmaceutical industry, it’s crucial to understand its basics. At its core, green chemistry aims to create chemical products and processes that reduce the use of hazardous substances.

Its principles include minimizing environmental impact and fostering innovation, efficiency, and safety in various industries. In pharmaceutical manufacturing, where complex chemical synthesis and rigorous quality standards are the norm, understanding green chemistry has become pivotal in a new era of sustainability and responsibility.

Consequently, green chemistry revolves around twelve guiding principles established by chemists Paul Anastas and John Warner. These principles encompass the design, synthesis, and utilization of chemical products. Also, these processes minimize environmental hazards and maximize efficiency. Some fundamental tenets included in green chemistry are waste prevention, using renewable feedstocks, energy efficiency, and designing safer chemicals and processes.

Reducing Environmental Impact

The pharmaceutical industry faces the challenge of minimizing its environmental footprint. Traditional processes use solvents, reagents, and procedures harmful to ecosystems and human health. Whereas, green chemistry provides innovative solutions without compromising product integrity. Some of these innovative solutions are:

Minimizing Waste Generation: Adopting continuous flow technologies and processes reduces waste volume, enhancing efficiency and mitigating pollution.
Embracing Renewable Feedstocks: Utilizing renewable biomass-derived feedstocks like plant oils and sugars minimizes reliance on finite fossil resources and lowers greenhouse gas emissions. Moreover, it promotes sustainability in pharmaceutical manufacturing.
Optimizing Energy Efficiency: By reducing heat and electricity consumption, maximizing process integration, and leveraging renewable energy sources, pharmaceutical companies can save money and help the environment. Also, it makes their processes work together better, and using renewable energy sources.

Enhancing Safety and Compliance

What comes next in this is enhancing safety and compliance. Ensuring safety and compliance is paramount in pharmaceutical manufacturing. Green chemistry aligns with regulatory efforts to improve safety standards and promote sustainable practices within the pharmaceutical industry and they are:

Minimizing Exposure to Hazardous Substances: Green chemistry aims to replace toxic substances with safer alternatives, reducing workplace risks and fostering responsible chemical management.
Meeting Regulatory Requirements: Adopting green chemistry ensures compliance with regulations like REACH and TSCA, demonstrating a commitment to sustainability and responsible stewardship.
Embracing Sustainable Development Goals: Green chemistry aligns with SDGs, integrating environmental, social, and economic considerations to combat climate change and promote equitable healthcare.

Optimizing Efficiency and Cost-effectiveness

In pharmaceutical manufacturing, efficiency and cost-effectiveness are crucial for companies aiming to stay competitive while meeting quality and affordability demands. It can be achieved by embracing green chemistry principles, as many green technologies offer cost savings and process optimization opportunities. Several of them are:

Streamlining Manufacturing Processes: Green chemistry advocates for simpler, more streamlined processes in pharmaceutical manufacturing. It aims to optimize reaction conditions and employs innovative techniques such as continuous flow chemistry. These approaches lead to improved productivity and cost-effectiveness.
Continuous Flow Chemistry: Continuous flow chemistry enables precise reaction control, reducing solvent usage and enhancing product quality and purity. It facilitates scale-up and agility in meeting market demands.
Reducing Raw Material Waste: Green chemistry minimizes waste by promoting atom-efficient reactions and renewable feedstocks. Metrics like atom economy and E-factor help assess efficiency, leading to less waste and lower environmental impact.
Enhancing Resource Efficiency: Efficient resource use, including energy and water, is central to green chemistry. Technologies like microwave synthesis reduce energy consumption, while bio-based materials lessen reliance on finite resources, mitigating environmental impact.

Innovating Drug Discovery and Development

Green chemistry is not limited to manufacturing; it’s also used in drug discovery and development processes. Traditionally, drug designs prioritize efficacy and potency without considering how they affect the environment. However, if we include environmental concerns when designing drugs, researchers can develop effective and environmentally friendly drugs. A few of them are:

Designing Eco-Friendly Molecules: In green drug discovery, designing molecules considers therapeutic effectiveness and environmental impact. It involves renewable feedstocks, safer solvents, and efficient synthetic routes guided by ecological profiles.
Biocatalysis and Enzyme Engineering: Enzymes catalyze reactions with high precision and biodegradability, enhancing sustainability. Tailored enzymes enable efficient synthesis of complex molecules, reducing environmental impact in drug discovery.
Green Synthesis Routes: Novel synthesis routes in green drug discovery minimize ecological impact and maximize efficiency. Continuous flow technologies control reactions, reducing waste and resource use for scalable, streamlined processes.
Collaborative Initiatives and Knowledge Sharing: Green chemistry’s full potential in drug discovery requires collaboration. Partnerships and platforms facilitate idea exchange, accelerating innovation for the widespread adoption of sustainable pharmaceutical practices.

Challenges and Roadblocks

Green chemistry promises transformative economic and environmental benefits, reshaping the industry towards sustainability and environmental stewardship. However, the widespread adoption of green chemistry in pharmaceutical manufacturing is not without challenges.

One major obstacle is the inertia of established practices and infrastructure, making it difficult for companies to transition to greener alternatives. Additionally, there may be technical hurdles and regulatory barriers to overcome, particularly when validating new processes and ensuring product quality and consistency.

These challenges require diverse solutions, including:

Basic training in process excellence and renewable energy use,
Provide financial incentives or awards for companies embracing greener alternatives,
Allocate funding for research and development focused on overcoming technical challenges,
Work with regulatory agencies to develop clear guidelines for green chemistry practices.

Conclusion

In a nutshell, green chemistry offers a promising pathway towards transforming pharmaceutical manufacturing into a more sustainable and environmentally responsible industry.

By prioritizing renewable feedstocks, minimizing waste generation, and enhancing safety and compliance, companies can reduce their environmental footprint and improve efficiency and cost-effectiveness.

Despite challenges such as entrenched practices and regulatory barriers, collaborative efforts and innovative solutions can pave the way for the widespread adoption of green chemistry principles, ushering in a greener future for pharmaceutical manufacturing.

Understanding APIs, Intermediates, and Finished Dosage Forms: A Guide for Pharma Professionals

Introduction

In the intricate landscape of pharmaceutical development and manufacturing, a fundamental understanding of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms is paramount for professionals in the field.

Each stage is crucial in ensuring efficacy, safety, and regulatory compliance, from the inception of a drug’s synthesis to its final formulation.

This guide aims to provide pharmaceutical professionals with a comprehensive overview of APIs, intermediates, and finished dosage forms, delving into their intricacies, and regulatory considerations within the pharmaceutical industry.

Active Pharmaceutical Ingredients (APIs)

APIs constitute the central ingredient of any drug formulation, providing pharmacological activity or other direct effects in disease treatment, prevention, or diagnosis. They are manufactured through chemical synthesis, fermentation, recombinant DNA technology, or isolation from natural sources.

Processes of API Manufacture

API Process Development and Production involves several processing stages, such as reaction, crystallisation, separation, purification, filter cake washing, solvent swapping, and solvent exchange.

API Process Development Stage: Following drug discovery and early formulation, scientists determine how to convert the Active Pharmaceutical Ingredient (API) into an appropriate dose form for pilot production. Methods devised during this stage are later scaled up for commercial manufacturing pending successful clinical studies.

Selection of Pharmaceutical Manufacturing Machinery: The choice of machinery for blending, extrusion, drying, milling, and micronization is critical. This selection significantly influences the final drug product’s physical characteristics and quality features.

Powder Processing and Particle Size Distribution (PSD): Powder processing involves milling, which reduces particle size for optimal processability, bioavailability, reactivity, and safety. Achieving the suitable particle size distribution (PSD) ensures drug efficacy and delivery to targeted body sites.

API Manufacturers

API production is a complex process involving chemical synthesis or biochemical methods. According to the FDA, Indian and Chinese companies dominate the API manufacturing sector. Pharmaceutical companies usually adhere to their country’s safety standards when manufacturing the final product.

Regulatory Compliance and Safety

The safety and efficacy of drug products hinge on the quality of their active ingredients, ensured through optimised processes.

Poor API process development and production, along with contaminated active ingredients, are linked to adverse health effects, including fatalities. Thus, regulatory procedures for approving active ingredients are being strengthened globally.

This regulation bolsters the pharmaceutical supply chain, enhancing medication quality and safety. APIs undergo independent pre-qualification processes, ensuring adherence to WHO Good Manufacturing Practices (GMP) and streamlining FPP pre-qualification.

API Intermediates

Pharmaceutical intermediates are chemical compounds synthesised and used to produce active pharmaceutical ingredients (APIs). They are formed at various stages in API synthesis and facilitate API synthesis by serving as building blocks or precursor molecules. They undergo chemical modifications to create the desired API.

Role of Intermediates in API Synthesis

Intermediates play a vital role in API synthesis by enabling controlled modifications for desired chemical properties. They represent various stages in the synthesis pathway toward the API, contributing significantly to the efficiency, scalability, and quality of the synthesis process. Well-designed intermediates can simplify complex routes, enhance yield, and reduce costs.

For example, a common intermediate in API synthesis is [benzene], which can be modified to produce a wide range of APIs. This versatility is one of the reasons why intermediates are so important in API synthesis.

Examples of Pharmaceutical Intermediates

Key Intermediates: Central to API synthesis, these intermediates undergo multiple transformations to form the desired API structure.
Protecting Group Intermediates: Involving temporary modifications of functional groups in the API molecule, protecting groups prevents undesired reactions.
Salt Formation Intermediates: APIs are sometimes produced as salts to enhance stability and solubility.
Chiral Intermediates: Introduce handedness into APIs, enabling the production of specific forms.

Regulatory Consideration:

Pharmaceutical intermediates are subject to GMP guidelines for quality control, compelling manufacturers to establish appropriate systems and processes. To ensure safety and quality, they must identify and control synthesis-related impurities as regulatory authorities require.

Process validation is necessary to maintain consistent quality in manufacturing, with manufacturers obliged to demonstrate process capability to meet specified standards. Additionally, comprehensive documentation is vital for traceability and regulatory assessment, ensuring integrity and compliance throughout the pharmaceutical intermediate manufacturing process.

Finished Dosage Forms (FDFs)

A finished dosage form (FDF) represents the consumable, finalised drug product. It encompasses tablets, pills, liquid solutions, and other forms of FDFs. All FDFs contain an API along with other inactive components.

Different types of FDF

There are various types of finished dosage forms, each with unique properties and applications:

Tablets: Tablets are solid dosage forms containing API and excipients. They come in multiple shapes, sizes, and colours, and can be designed for immediate release, extended release, or enteric coating.
Capsules: Capsules are solid dosage forms encapsulating API and excipients in gelatin shells. They come in two main varieties: hard capsules (powder, granules, or pellets) and soft capsules (liquid or semi-solid fill).
Liquids: Liquid dosage includes solutions, suspensions, and syrups. These are commonly used for paediatric and geriatric patients and individuals who have difficulty swallowing solid dosage forms.
Ointments: Ointments are semi-solid dosage forms often used for topical application. They are typically a combination of an API and a base and are used for dermatological, respiratory, and ophthalmic purposes.
Inhalants: Inhalants are intended to be inhaled into the lungs. They can be metered-dose inhalers, dry powder inhalers, or nebulized solutions and are often used for respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Regulatory Oversight

The FDA mandates manufacturers to demonstrate the efficacy of medications through laboratory settings and clinical trials involving actual patients. Stricter criteria and inspections have been implemented to regulate medications produced outside the home countries of pharmaceutical corporations.

Conclusion

Understanding APIs, intermediates, and finished dosage forms is pivotal for pharmaceutical professionals. The production of APIs encompasses rigorous processes, impacting the efficacy and safety of drug products from development to manufacturing.

Regulatory compliance ensures quality and safety, with intermediates playing a vital role in API synthesis. Diverse finished dosage forms cater to various patient needs. They are regulated to ensure efficacy and safety. Strengthening regulatory oversight is crucial for maintaining medication quality and safety and safeguarding public health globally.

Innovations in Nephrology Care: Exploring the Latest Treatment Options

Introduction

Nephrology emerged as the leading internal medicine subspecialty post-WWI. Kidneys are vital for bodily function, filter waste, regulate fluids and minerals, control blood pressure, and produce urine and erythropoietin.

Moreover, individuals with kidney disease experience impairment in kidney function, often stemming from conditions such as hypertension and diabetes.

The National Kidney Foundation reports that kidney disease affects roughly 37 million adults, while an additional 80 million are at risk. Additionally, racial minorities have a higher incidence of kidney disease, with African Americans being approximately four times as susceptible.

In this article, let’s learn more about the kidney, kidney diseases, and worldwide research.

What is Nephrology

Nephrology is a vital medical branch specializing in the comprehensive study, diagnosis, and treatment of kidney-related diseases. This involves a multifaceted approach, employing clinical, laboratory, imaging, and histopathologic techniques to assess kidney function and structure.

On the other hand, Nephrologists are dedicated to preserving kidney health through tailored interventions, including dietary adjustments, medication, and kidney replacement therapy. They adeptly manage various complications such as hypertension, fluid retention, and electrolyte imbalances, ensuring holistic care for their patients.

Moreover, Nephrologists play a crucial role in addressing chronic conditions like diabetes and hypertension, which significantly impact kidney function, alongside managing acute renal failure cases. Collaborating seamlessly with transplant teams, they extend their expertise to oversee the care of kidney transplant recipients, ultimately striving to enhance patient quality of life and prevent complications.

Areas of Focus in Nephrology

Nephrologists may focus on diagnosing and treating various kidney disorders, catering to specific patient groups, or conducting specialised procedures. Specialised areas within nephrology encompass:

Critical care nephrology
Diabetic kidney disease management
Dialysis oversight
Geriatric nephrology (for age 65+)
Interventional nephrology (including dialysis access and arteriovenous fistula surgery)
Renal oncology (kidney cancer)
Kidney stones treatment
Kidney transplant care
Paediatric nephrology (infants to adolescents)

Latest Treatment Options in Nephrology Care

Research and innovative developments shape treatment paradigms for kidney-related conditions in nephrology care. Some of these innovations are:

Kidney Fibrosis Treatment:

Researchers found increased histone lysine crotonylation (Kcr) in fibrotic kidneys, driven by the ACSS2 enzyme. Histone lysine crotonylation (Kcr) is a new acylation modification discovered in 2011 having important biological significance for gene expression, cell development, and disease treatment.

TGF-β for Improved CKD Treatment:

In Chronic Kidney Disease (CKD), TGF-β, a transforming growth factor affects kidney cell mitochondria, worsening the disease. However, in diseased conditions, TGF-β loses its anti-proliferative response and becomes an oncogenic factor.

Moreover, recent research shows blocking TGF-β in mice’s proximal tubules increases mitochondrial damage and inflammation. Similar issues were found in CKD patients’ kidney samples. Hence, this new insight may lead to new CKD treatment approaches targeting TGF-β pathways.

Denosumab in Osteoporosis Patients with Kidney Disease

In a recent innovation, Denosumab, commonly used for osteoporosis in advanced kidney disease patients, raises concerns about severe hypocalcemia. A study of 2804 older females on dialysis reveals a higher risk compared to oral bisphosphonates. Prolia now carries a boxed warning, emphasising intensified monitoring during treatment.

Genetic Solution to Mitigate CKD

New research reveals that certain APOL1 gene variations increase chronic kidney disease (CKD) risk in people of West African descent. However, another mutation, p.N264k, counters this risk. In vitro studies show that p.N264k reduces the harmful effects of high-risk APOL1 variations. This suggests potential drug targets for CKD prevention.

Enhanced Advance Care Planning for Dialysis Patients

A study in 42 dialysis clinics with 430 patients and their decision-makers showed improved patient-surrogate communication through 45-60 minute discussions led by clinic healthcare workers. This approach reduces end-of-life decisional conflicts and increases adherence to care goals among dialysis patients, enhancing their overall care experience.

Medicinal Options in Nephrology Care

Medicinal Options in Nephrology Care delves into the diverse pharmacological interventions available for managing kidney-related conditions.

Renaglob

Renagold Tablet is frequently prescribed as a nutritional supplement for individuals suffering from chronic kidney failure and uremia. Its primary function is to inhibit the elevation of urea levels in the bloodstream from consuming non-essential amino acids among kidney failure patients.

Uriglob/Uriglob D

Uriglob Tablet effectively relaxes muscles in the bladder and prostate to alleviate symptoms associated with an enlarged prostate. This relaxation enables easier urination, providing rapid relief from urinary difficulties.

Trientine HCL Capsules

Trientine Hydrochloride is prescribed for Wilson’s disease, functioning as a copper-chelating agent. Its mechanism involves binding surplus copper in the body’s tissues and facilitating its elimination through the kidneys in the urine.

Selaglob

Trientine Hydrochloride reduces high blood phosphorus levels in dialysis patients. Selaglob Tablets stop phosphate absorption in the intestine, reducing blood phosphate levels.

Kalara

Calcium Polystyrene Sulfonate reduces high blood potassium levels, particularly in kidney conditions such as anuria, severe oliguria, and chronic kidney disease. It’s also utilised to lower potassium levels in patients undergoing regular dialysis.

Febuglob

Febuglob Tablet treats gout by lowering uric acid levels. It’s for patients unresponsive to allopurinol. Also used for hyperuricemia in adults with hematologic malignancies at medium to high TLS risk during chemotherapy.

Deferglob

Deferglob Tablet is prescribed for managing chronic iron overload resulting from recurrent blood transfusions. Its function involves eliminating surplus iron from the body and lowering the likelihood of organ damage induced by iron accumulation.

Conclusion

Innovations in nephrology care are revolutionising treatment approaches for kidney-related conditions, addressing diverse challenges with promising solutions.

The landscape of nephrology is evolving, from groundbreaking genetic insights offering potential preventive strategies for chronic kidney disease to enhanced communication practices improving end-of-life care for dialysis patients. Furthermore, advancements in medicinal options provide tailored interventions, such as Renagold for nutritional support and Trientine HCL for Wilson’s disease.

These developments underscore nephrology’s commitment to optimising patient outcomes and enhancing the quality of life, ushering in a new era of personalised and effective kidney care.

Globela Pharma offers high quality and affordable nephrology solutions across 50+ countries.

Beyond the Virus- The Connection Between CVD and COVID-19 Complications

Introduction-

The world witnessed a catastrophe in the form of the COVID-19 pandemic. As per statistical data, more than 702 million active Covid positive cases are present worldwide. Moreover, the world lost around 7 million to the deadly virus. The COVID-19 is characterised by severe respiratory distress syndrome caused by novel SARS-CoV-2.

At the beginning of COVID-19, evidence of the acute symptoms of the pandemic was pretty straightforward. However, several studies are being carried out to analyse the long-term sequelae of COVID-19. Reports of the trials suggest a strong link between COVID-19 and Cardiovascular Diseases.

According to the World Health Organization, Cardiovascular Diseases are the leading cause of mortality worldwide. Heart attack and stroke are significant CVDs that have high mortality prevalence. The data put forward by a report, COVID-19 and Cardiovascular Diseases, published in 2020, stated a high occurrence of CVDs in COVID-19-positive patients, with more than 7% of patients experiencing myocardial injury due to the virus.

Therefore, the identification of risk factors and prevention of cardiovascular diseases in patients with a COVID-19 history is a challenge for the medical fraternity. Risk factors associated with cardiovascular diseases are well known, such as lifestyle and genetics. However, the role of these two factors in precipitating CVDs in patients affected by SARS-CoV-2 is still unknown.

COVID-19 and CVDs

One of the long-term consequences of the pandemic manifested in the form of an increased global cardiovascular burden. Recent statistical data presents a rise in mortality and morbidity related to Cardiovascular diseases owing to the direct and indirect effects of COVID-19.

Moreover, research has found an interlink between genetic factors and poor lifestyle with cardiovascular disorders in COVID-19 patients.

The genetic association is determined using the Polygenic Risk Score. High values show a high risk of developing coronary artery disease, atrial fibrillation and venous thromboembolism in people with SARS-CoV-2 infection. Similarly, poor living habits such as smoking habit, increased alcohol consumption, and sedentary living put individuals at a higher risk for developing cardiac complications.

Although the exact pathophysiology behind the risk of CVD in COVID-19 patients is not yet understood, researchers have attempted to explain a couple of mechanisms. Some of them are:

Direct cardiotoxicity- The SARS-CoV-2 virus directly infects the cardiac cells leading to myocarditis.

Post-disease hyper-inflammation- Post-COVID-19 cases have shown uncontrolled release of cytokines leading to plaque formation and vascular inflammation. It ultimately precipitates Myocardial Infarction, cardiomyopathy and Heart Failure.

Systemic manifestations- COVID-19 also causes systemic complications such as Disseminated Intravascular Coagulation(DIC), sepsis etc which result in cardiovascular diseases.

Genetics and Lifestyle- Potent Risk Factors for CVD

Genetics and lifestyle influence the occurrence of cardiovascular diseases. A family history of CVD raises the chances of acquiring the disease. The proportion of risk will also be influenced by the age of the affected relative. CVDs such as congenital diseases, high cholesterol levels, and high blood pressure can be inherited. Alteration even in the single gene code can lead to heritable cardiac disorders.

Similarly, lifestyle also influences the prevalence of CVD in an individual. Poor diet, high alcohol consumption, a history of smoking, and less physical activity are culprits of cardiac diseases.

But, how do these two potential risk factors augment the chances of CVDs in people who have a history of COVID-19?

What does Research Show?

A study was conducted between March 2020 and September 2021 on 25,335 COVID-19-positive patients to evaluate the role of genes and lifestyle. The study aimed to correlate the link between PRS(Polygenic Risk Score), lifestyle factors and cardiovascular disorders in selected patients within 90 days after diagnosis of COVID-19.

A polygenic Risk Score is an accumulation of genetic risk factors for a particular trait. It is an authentic tool to predict precision medicine and cardiovascular disease occurrence rates. In the study, the PRS was determined for cardiac diseases such as venous thromboembolism, coronary artery disease, atrial fibrillation and ischemic strokes. Moreover, the prospective cohort research also used a lifestyle index comprising 9 variables to determine its role in the precipitation of cardiovascular diseases.

The study used the Cox proportional hazard model to calculate the hazard ratio and confidence interval for studying the link between genes and CVD. In contrast, the multivariable Cox regression model was applied to determine the lifestyle factors.

The result of the study confirmed a linear association between gene mutations and a higher incidence of cardiovascular disorders post-COVID-19 infection. The participants with the top 20 per cent Polygenic Risk Score have a high risk of developing atrial fibrillation(3-fold increase), coronary artery disease(3.5-fold increase) and venous thromboembolism (2-fold rise). However, no apparent association is observed between ischemic strokes and genetic factors. Another interesting finding is the positive existence of risk factors even in fully vaccinated individuals.

A positive correlation exists between a healthy lifestyle and a lower incidence of CVDs in COVID-19 patients. It is also noteworthy that COVID-positive cases with unhealthy lifestyles, when switched to healthy living diminished their risk of developing CVDs. Cardiac complications such as CAD and AF also demonstrate an additive rise in patients with high scores of PRS and an unhealthy lifestyle.

The Conclusion

Although the fatal wave of the pandemic is over. The world lost more than a million lives. But, the threat persists. The long-term consequences of COVID-19 in patients with a positive history are still a medical mystery. Several research groups and pharmaceutical companies like Globela Pharma are trying to do evidence-based studies to deal with chronic complications.

Cephalosporins Today: Current Applications and Impact on Modern Medicine

Introduction:

Welcome to a comprehensive exploration of Cephalosporins, a pivotal group of antibiotics derived from Cephalosporium. In this blog, we’ll delve into their mechanism of action, examine the different generations, explore their diverse applications, and peer into the future with the emergence of the fifth generation. Join us on this journey through time and innovation in the realm of antibiotic therapy.

Cephalosporins- The Future of Antibiotics

Cephalosporins are a group of semisynthetic antibiotics derived from Cephalosporin-C, obtained from the fungus Cephalosporium. These are the largest group of Beta-Lactam antibiotics, i.e., they interfere with bacterial cell wall synthesis. Cephalosporins are broad-spectrum antibiotics effective against both gram-positive and gram-negative bacteria. Therefore, its use is widespread in both medical and dental conditions.

There are five generations of cephalosporins divided based on chronological sequence of development as well as antibacterial spectrum and potency.

The generation of cephalosporin determines the indications, contraindications, adverse effects, and route of administration, along with other vital factors.

Mechanism of Action-

The beta-lactam drugs inhibit cell wall formation by acting against the transpeptidase. This disrupts the cross-linking that maintains the close-knit structure of the cell wall. The transpeptidase and related proteins constitute the penicillin-binding proteins(PBPs) located in the bacterial cell membrane. Each microorganism has multiple PBPs that have an affinity towards different beta-lactam antibiotics. Therefore, when a bacteria replicates in the presence of a beta-lactam antibiotic, cell wall-deficient organisms are produced.

Moreover, owing to the hyperosmotic interiors of the bacteria, the cell wall deficient form swells and bursts, thus causing the lysis of the organism. This is how a beta-lactam antibiotic such as cephalosporins exerts bactericidal action. Beta-lactam antibiotics are most lethal during the phase of rapid cell wall synthesis. And because the peptidoglycan cell walls are unique to bacterial species, these antibiotics are practically non-toxic to humans. Also, blood, pus, and tissue fluids do not interfere with the antibacterial action of beta-lactam antibiotics.

Generations of Cephalosporins-

Based on their activity and potency against the type of bacteria, traditionally there are four generations of cephalosporins-

First Generation- These were developed in the 1960s and have high potency against gram-positive bacteria such as staphylococci and streptococci. However, their action against gram-negative groups is considerably low. Proteus mirabilis, Klebsiella, and E. coli are a few gram-negative species responsive to first-generation cephalosporins.

The first-generation cephalosporins include Cefazolin, Cephalexin, Cephradine, and Cefadroxil.

Second Generation- Developed after the first generation of cephalosporins, this group of drugs works against gram-negative bacteria. Some second-generation compositions are also effective against anaerobes(cephamycin sub-group).

Second-generation cephalosporins include cefuroxime, which is highly active against H. influenza. Other drugs in this group are Cefuroxime axetil, cefaclor, etc.

Third Generation- First introduced in the 1980s, the third generation cephalosporins have high augmented activity against gram-negative Enterobacteriaceae. Some of the formulations also inhibit Pseudomonas activity. All the third-generation cephalosporin drugs are resistant to the beta-lactamase enzyme produced by gram-negative bacteria. However, they are less potent against gram-positive cocci and anaerobes. Cefotaxime is the prototype of this group. Other drugs include Ceftizoxime, Ceftriaxone, Ceftazidime, Cefixime, etc.

Fourth Generation- This generation includes Cefepime, developed in the 1990s. It has a similar activity spectrum as the third-generation drugs. However, its potency is more with high resistance to beta-lactamases. Cefepime is also active against Ps. aeruginosa and Staph. Aureus. Another fourth-generation cephalosporin is Cefpirome. Both of these drugs are highly recommended for hospital-acquired infections and other serious health issues.

Applications of Cephalosporins-

Cephalosporins are extensively used in medical practice. The group of beta-lactam antibiotics have found a wide range of applications.

As a substitute for the Penicillin group of antibiotics in allergic patients. The first generation Cephalosporins are the preferred choice.
For Respiratory, urinary and soft tissue infections caused by gram-negative organisms, especially Klebsiella, Proteus, Enterobacter, and Serratia.
Against Penicillinase-producing staphylococcal infections.
In cases of septicemia caused by gram-negative organisms. A combination of aminoglycoside and cephalosporin is a good combination in such cases.
Cefazolin is administered for most of the surgical prophylaxis.
Ceftriaxone is the first choice of drug(as a single-dose therapy) for gonorrhoea caused by penicillinase-producing organisms.
Cefuroxime and cefotaxime are also preferred for single-dose therapy in cases of chancroid.
Ceftriaxone and cefoperazone are the fastest-acting drugs in typhoid.
Cefuroxime, cefaclor or any of the third-generation compounds is a choice of drug for mixed aerobic-anaerobic infections in cancer patients.
Third-generation cephalosporins are given in colorectal surgery and obstetric complications.
Ceftazidime or other third-generation cephalosporins are administered as a prophylactic agent or treatment modality in cases of infections in neutropenic patients.
These are a preferred group of drugs given against hospital-acquired infections that are resistant to common antibiotics.
Orally active 1st and 2nd generation cephalosporins are primarily prescribed for orodental infections.

Adverse Effects of Cephalosporins

Cephalosporins are a well-tolerated group of drugs. However, they are more toxic than penicillin. Some of the adverse effects related to cephalosporins are-

Pain after intramuscular cephalosporin administration is a common occurrence.
Thrombophlebitis on intravenous injections occurs in many cases.
Oral administration of cephradine can lead to diarrhea. Parenteral administration of cefoperazone is significantly excreted in bile.
Hypersensitivity reactions similar to penicillin. However, the incidence rate is lower. Rashes are a common manifestation. Anaphylaxis, urticaria, and asthma can also occur.
Few cephalosporins such as Cephalothin exhibit low-grade nephrotoxicity. Pre-existing renal conditions usually accentuate the condition.
Bleeding can occur on administration of cephalosporins like cefoperazone and ceftriaxone.
The rare occurrence of neutropenia and thrombocytopenia is also noticed with ceftazidime and some other cephalosporins.
Cefoperazone also creates a disulfiram reaction with alcohol.

Contraindications of Cephalosporins-

Although well-tolerated, cephalosporins are contraindicated in the following few conditions-

Ceftriaxone is contraindicated in neonates with hyperbilirubinemia.
In patients who are allergic to cephalosporins.
In individuals who have a history of anaphylaxis to penicillin or other beta-lactam group of drugs.

What is new? The Fifth Generation Cephalosporins

The research work with cephalosporins has seen a dramatic rise in the last decade. Novel cephalosporins such as ceftobiprole, ceftolozane, ceftazidime etc offer excellent in vitro results in terms of microbiological susceptibility. These drugs are considered to be the fifth-generation cephalosporins. These compounds have transport mechanisms to enter multi-drug-resistant bacteria. These drugs work via a sparing approach in different antimicrobial classes such as carbapenems, aminoglycosides etc.

However, more research is required to evaluate their clinical efficacy. Pharma groups like Globela Pharma can contribute to developing and testing the fifth class of cephalosporins which will be a game changer.

Conclusion:

As we conclude this journey through the past, present, and future of Cephalosporins, the potential for groundbreaking advancements in antibiotic therapy becomes evident. With ongoing research and the emergence of the fifth generation, the horizon is broadening for medical professionals and pharmaceutical companies alike. Stay tuned for the latest updates in the dynamic world of antibiotic innovation!